atezolizumab + cisplatin + carboplatin + etoposide

Atezolizumab + cisplatin + carboplatin + etoposide is a combination regimen used in oncology, primarily for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and being investigated for poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC)[1][2][4][6][8]. - Atezolizumab is a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death ligand 1 (PD-L1), thereby enhancing T-cell–mediated anti-tumor responses. - Cisplatin and carboplatin are platinum-based chemotherapeutic agents that induce cytotoxicity mainly via DNA cross-linking and damage, promoting apoptosis and immunogenic cell death. - Etoposide is a topoisomerase II inhibitor, blocking DNA replication and repair, leading to cancer cell death. - The combination exploits both direct cytotoxic effects and immune modulation; platinum agents can enhance antigen presentation, and atezolizumab augments anti-tumor immunity, particularly in tumors with suppressed adaptive immune responses[3][6][8]. - The regimen is considered in both first-line approved and experimental contexts for small cell lung cancer and neuroendocrine neoplasms, with several trials ongoing[2][4][6][8].

Brand names

Tecentriq

Other names

EC/EP + atezolizumabetoposide/carboplatin or etoposide/cisplatin plus atezolizumabEP/EC plus atezolizumab